|

Quemliclustat Clinical Trials

1 actively recruiting trial across 1 location

▼ -1 trial since June 2026

Also known as: AB680

Pipeline

Phase 2: 1

Top Sponsors

  • Catherine Spina1

Indications

  • Oligometastatic Prostate Cancer1
  • Cancer1

New York, New York1 trial

Adenosine Signaling Modulation and Immune Checkpoint Inhibition With Hormone Sensitive Oligometastatic Prostate Cancer

Columbia University Irving Medical Center / NewYork-Presbyterian Hospital

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.